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Materials and Methods
Clinical Samples and Cell Lines
Primary gastric samples were obtained from the Singapore Health Services (SingHealth) and the National University Hospital System (NUHS) tissue repositories, with signed informed patient consent and approvals from the respective institutional Research Ethics Review Committees. Clinical information was collected with Institutional Review Board approval. There was no pre-specified sample size calculation since this is a hypothesis generating discovery study. Clinical characteristics of patients analyzed in this study are presented in Supplementary Table S1 . GC cell lines were obtained from commercial sources (American Type Culture Collection, Japan Health Science Research Resource Bank) or from collaborators (Yonsei Cancer Centre, S. Korea).
DNA and RNA Extraction
Genomic DNA was extracted from flash-frozen tissues and cells using a Qiagen genomic DNA extraction kit. Total RNAs was extracted using Trizol (Invitrogen, CA), digested with RNase free DNase (RQ1 DNase, Promega), and subsequently purified using an RNeasy Mini kit (Qiagen,CA).
Copy Number Profiling and GISTIC Analysis
Genomic DNAs from gastric tumors and matched non-malignant gastric tissues (normal) were hybridized on Affymetrix SNP6 genotyping arrays and processed as follows:
Step 1) Normalization: Raw SNP6 CEL files were processed using Affymetrix Genotyping Console 4.0. A reference file was first created from the SNP6 CEL files of normal gastric samples (98 samples). The 193 tumor SNP6 CEL files were then normalized against this normal reference file.
Step 2) Segmentation: Copy number segmentation data was produced using the Circular Binary Segmentation (CBS) algorithm using the R package DNAcopy [1] for both tumor and normal gastric samples. The p value cutoff for detecting a change-point was 0.01, with a permutation number of 10000.
3) GISTIC Analysis: The GISTIC algorithm [2] was used to identify genomic regions with recurrent copy number alterations. GISITC was applied to the CBS-segmented files of tumors, and filtered through a CNV (copy number variation) file constructed from the segmented data of normal samples to identify somatic tumor-specific CNAs. GISTIC reports regions of interest with an associated q-value, which is obtained by multiple hypotheses correction. Genomic regions with q-value<0.25 for broad regions and qvalue<0.001 for focal regions were considered significant. Proportions of CNA for individual normal and tumor sample was defined as: size of CBS regions with CNA per sample divided by the sum of all autosome lengths. Chromosomal instability values for GCs were estimated by the number of cytobands exhibiting CNA for each sample, calculated by averaging the CBS segmented value for each cytoband.
The SNP6 copy number data has been deposited into the National Centre for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO) website, series accession number GSE31168.The Reviewer link is http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=tbqtnokgaooucjo&acc=GSE31168
DRP: Identification of Mutually Exclusive and Co-Altered CNAs
To identify significant relationships between regions of frequent CNA, we implemented a dimension reduction permutation (DRP) statistical algorithm adapted from a previous study analyzing patterns of somatic DNA mutations in tumor [3] . To determine the significance of any specific mutually exclusive (ME) or co-alteration (CA) interaction, we compared the numbers of samples exhibiting a particular ME or CA interaction against a null distribution of interactions obtained by randomly permuting the genomic alterations across samples and genes (100,000 permutations), while taking into consideration the prevalence of genomic alterations. Essentially, for each permutation, we constrained the number of samples with genomic alterations and the number of genes exhibiting alterations within each sample to be similar to the original data. Empirical pvalues of <0.05 were considered significant. An in-depth description of the DRP methodology is presented in Text S1, and the DRP software can be downloaded from http://research.duke-nus.edu.sg/papers/DRP.zip.
FISH and Immunohistochemical Analysis
KRAS and FGFR2 FISH was performed using BAC clones obtained from the BACPAC resources center (CHORI, Oakland, CA USA). BAC DNA was labeled using a Bioprime DNA labeling kit (Invitrogen, Carlsbad, CA, USA). FISH was performed on metaphase spreads (cell lines) or on FFPE sections after deparaffinization (clinical specimens).
Target DNA probes were labeled using spectrum green and control probes in spectrum orange (centromeric CEP probes for chromosomes 10 and 12) (Abbott Molecular Inc, Des Plaines, IL, USA). Hybridized slides were counterstained with DAPI and analyzed using a Olympus BX50 fluorescence microscope. Nuclei were scored for amplification by comparing signals from internal controls (CEP probes) against target gene signals (KRAS, and FGFR2). For ERBB2 immunohistochemistry, we analyzed 146 of the 193 tumors, representing all cases for which we were able to obtain full sections. The remaining 47 cases were not analyzed for a variety of reasons, including failure to retrieve the samples due to historical storage arrangements (archival samples are stored off-site at our center) and insufficient material due to exhaustion of the FFPE blocks (small tumors). Sections of archival formalin-fixed, paraffin-embedded tissue (3 µm) were placed on slides coated with poly-L-lysine. After deparaffinisation and blocking of endogenous peroxidase, ERBB2 immunostaining was performed using rabbit anti-human c-erbB-2 oncoprotein as primary antibody (Dako Corp, Carpinteria, CA, USA) at 1/100 dilution. Binding of the primary antibody was revealed by means of the Dako QuickStaining, Labelled Streptavidin-Biotin System (Dako), followed by the addition of diaminobenzidine as a chromogen. ERBB2 immunoreactivity was evaluated by an experienced pathologist (LKH) according to the scoring system of [4] . CSMD1 immunohistochemistry was performed on full sections as described in [5] 
DNA Sequencing, Mutation Genotyping and Quantitative PCR
DNA products corresponding to the coding regions of target genes were amplified by PCR and were subjected to cycle sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on a 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA, USA). KRAS mutation genotyping was performed by both Sanger sequencing (139 GCs) and mass-spectrometry based genotyping (Sequenom MassARRAY) (94 GCs). Reference sequences were obtained from the Ensembl Genome Browser database. Quantitative real-time PCR was performed on an ABI 7900 HT instrument using FGFR2 intron 2 primers. Reaction mixes consisted of 5ul SYBR green PCR master mix (ABI), 1ul FGFR2/LINE1 primers, 20ng (0.5ul) of genomic DNA template in a final reaction volume of 10ul. All experiments were performed in triplicate. FGFR2 cycle thresholds were normalized to the LINE1 repeat element from the same samples, as an endogenous control. Normal human genomic DNA was chosen as the calibrator and for each analysis a negative control was also prepared using all reagents except DNA template.
Gene Expression Analysis
Of the 193 tumors profiled on Affymetrix SNP6 arrays (Affymetrix, Santa Clara, CA, USA), 156 tumors had corresponding gene expression data available along with 100 normal gastric samples on Affymetrix U133P2 arrays (this cohort is analyzed in Figure   4C ). Additional details of the gene expression data set are presented in [6] and are publicly available at GEO under accession number GSE15460. To analyze FGFR2 mRNA survival associations in Figure 4D , we analyzed a combined GC gene expression data set of 398 tumors. The 156 patients analyzed in Figure 4C form a subset of the 398 patients. To establish this combined data set, we combined gene expression data from GSE15460 and three other GC cohorts from Singapore (U133AB), Australia (AU) and the University of Leeds, UK (UK). Clinical information for these gene expression data sets is provided in Table S6 . Briefly, individual arrays were normalized using the MAS5 algorithm, and batch effects removed using the COMBAT algorithm [7] .
Clinico-Pathologic Correlation Analysis
Survival curves were estimated using the Kaplan-Meier method, with the duration of survival measured from the date of surgery to date of death or last follow-up visit.
Overall survival was used as the outcome metric. Patients who were still alive or lost to follow-up at time of analysis were censored at their last date of follow up. Univariate and multivariate survival analysis was performed using the Cox proportional hazards regression model. Besides genetic factors (e.g. FGFR2, KRAS), other clinical factors considered in the multivariate model included grade and stage which were also significant in univariate analysis. Associations with other clinical variables were performed using the Fisher Exact Test, at a significance threshold of p<0.05.
Reverse Transcription-PCR (RT-PCR) and Western Blotting Analysis
For mRNA analysis, equal quantities of RNA were reverse transcribed using SuperScript Fluorescence secondary antibodies (Thermo Scientific) and imaged using LI-COR Odyssey. Experiments were repeated a minimum of three independent times.
Cell Proliferation Assays and Drug Treatments
Cell proliferation assays were performed using the CellTiter 96 ® AQ ueous One Solution
Assay kit (Promega) and the plates were measured using a PerkinElmer plate reader.
Each assay was performed in triplicate, and the results were averaged over three independent experiments. Dovitinib was provided by Drs. D. Graus-Porta and C. Garcia- GI50 values for Dovitinib, representing the concentration at which 50% cell growth inhibition is achieved for 48 hours of treatment, were computed using the GI50 calculation formula at http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
Cell Death and Colony Formation Assays
Caspase 3/7 assays were performed using the Caspase-Glo® 3/7 Assay kit (Promega, WI, USA) and the plates were measured using a Tecan plate reader. Three independent experiments were performed and each assay was performed in triplicate. GC cells were seeded in 96-well black plates and treated with Dovitinib using the same method as the cell proliferation assays. For colony formation assays, base layers of 0.5% Gum Agar in 1x McCoy's 5A and 10% FBS were poured into 6-well plates and allowed to harden at 4°C. After siRNA transfection, overexpression, or drug treatment, 50 000 cells/well were seeded in complete media plus agar mixture at 42°C and seeded on top of the solidified base layer. Plates were incubated at 37°C in for 3-4 weeks, during which plates were fed drop-wise with complete media. After 3-4 weeks, plates were photographed using the Kodak GL 200 System (EpiWhite illumination). Each assay was performed in triplicate, and the results were averaged over three independent experiments.
Xenograft assays
Efficacy of dovitinib was evaluated and compared to the positive control drug 5-FU in a primary human gastric cancer xenograft model (n= 10 in each group). This tumor model was derived from a primary gastric cancer from Chinese ethnicity and is confirmed with respectively. Frequencies were summarized for co-altered (N CA >=O CA ) and mutually exclusive associations (N ME >=O ME ). Empirical p-values were then computed against these frequencies under the null hypothesis. This table lists all significant mutually exclusive (ME) and co-occurring (CO) interactions for a pair of genes ('Gene1' and 'Gene2').
Supplementary Tables
The columns are : '#Gene1' and '#Gene2' are the observed frequency of amplification for each pair of genes. '#Both' indicates the observed number of cases of coamplification for this pair of genes, and '#OnlyOne' indicates the observed number of cases for amplification in only one of this pair of genes. '#BothExp' and '#OnlyOneExp' are the expected results from the DRP permutation for coamplification cases and non-coamplification cases. 'PvalueME' and 'PvalueCO' are the empirical pvalues for ME and CO interactions. 'QvalueME' and 'QvalueCO' are converted Storey's qvalue. Gene pairs related to RTK/RAS signaling are highlighted.
Significant ME interactions are at the top of the list, while significant CO interactions are at the bottom.
Gene1
Gene2 #Gene1 #Gene2 #Both #OnlyOne #BothExp #OnlyOneExp PvalueME QvalueME PvalueCO QvalueCO Significant p-values are shown in bold type. *Genomic Instability was inferred based on the number of copy number altered cytobands for each tumor sample (methods). 
